TMS Co., LtdJP:4891Cash flow

Market cap
¥6.2B
P/E ratio
Timbs Inc. develops anti-inflammatory drugs from black mold compounds, targeting diseases like stroke and inflammatory conditions through partnerships with major pharmaceutical companies.
2021/022022/022023/022024/022025/022025/12
Depreciation & amortization417740
Cash from operations -7381,262-688-823-494-780
Capital expenditures-0-4-13-3-31-3
Cash from investing -0-17-14-3-31-3
Cash from financing 1,1012461,6896881641
Free cash flow
FCF margin (%)-----